|
|
Article: $425 Million Cephalon Civil Settlement and Criminal Fine; In America's Largest Biotechnology Medicaid Fraud Case; Qui Tam Whistleblower Attorney Brian P. Kenney, Esq. Filed First Complaint With Client's Off-Label Marketing Allegations In 2003; Additional.
- Article from:
- Cancer Weekly
- Article date:
- October 14, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biotech drug manufacturer Cephalon, Inc. ("Cephalon") flouted federal regulations on a grand scale for years by off-label marketing its first three prescription drugs far beyond the cancer pain, epilepsy and narcolepsy specialists for whose patients those drugs had been FDA-approved. Instead, Cephalon focused its national marketing muscle on unapproved uses, targeting medical specialists with bigger patient populations, according to a Complaint filed in 2003 by Philadelphia qui tam whistleblower attorney Brian P. Kenney, Esq. The complaint was unsealed today with Cephalon's $375 million nationwide Medicaid fraud settlement and $50 million corporate criminal plea (see also ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cephalon Exceeds Both Sales and Earnings Guidance for ...
Cancer Weekly;
August 12, 2008 ;
700+ words
... ... company's website at www.cephalon.com and clicking on ... Biotechnology Company, Cephalon, Doxorubicin Hydrochloride ... Therapy, Treatment, Cephalon Inc. This article was prepared by Cancer Weekly editors from staff and other ...
|
|